Intervention: Ibodutant
Trial phase: Phase 3
SMILES: Cc1ccc2cc(C(=O)NC3(C(=O)N[C@H](Cc4ccccc4)C(=O)NCC4CCN(CC5CCOCC5)CC4)CCCC3)sc2c1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 271
Group description: Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will be re-randomised at week 13 in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.

Ibodutant 10 mg: Oral tablet, to be given once daily.
Eligibility criteria:
Inclusion Criteria:

At screening:

Female patients aged 18 years or older.

Clinical diagnosis of IBS-D according to the following symptoms-based criteria as per Rome III modular questionnaire criteria:

Recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months associated with at least 2 of the following characteristics: a) improvement with defecation; b) onset associated with a change in the frequency of stool; c) onset associated with a change in form (appearance) of stool.
Symptom-onset at least 6 months prior to diagnosis.
Loose or watery stools at least 25% of the time in the last 3 months AND hard or lumpy stools less than 25% of the time in the last 3 months.
Additional criterion: more than 3 bowel movements per day at least 25% of the time in the last 3 months.
For patients older than 50 years OR patients with a positive family history of colorectal cancer: normal results from colonoscopy/flexible sigmoidoscopy performed within the last 5 years.
For patients aged 65 years or older: absence of ischaemic colitis, microscopy colitis or any other organic gastrointestinal disease as evidenced by the results of a colonoscopy/flexible sigmoidoscopy with biopsy performed within 6 months.
For women of childbearing potential: Use of a highly effective contraceptive method with a failure rate <1% per year throughout the entire study period.
Physical examination without clinically relevant abnormalities during screening.
No clinically relevant abnormalities in 12-Lead ECG or in laboratory findings.
Mentally competent, able to give written informed consent, and compliant to undergo all visits and procedures.
Unrestricted access to a touch-tone telephone.
Willingness to refrain from using loperamide within 3 days prior to run-in visit and during the run-in period.

Additional criteria at randomisation:

During both weeks of the run-in period:

A weekly average of worst abdominal pain in the past 24 hours with a score of ≥3.0 on a 0 to 10 point scale.
At least one bowel movement on each day.
A weekly average of at least 3 bowel movements per day.
At least one stool with a consistency of Type 6 or Type 7 according to the Bristol Stool Scale (BSS) on at least 2 days per week.
Less than 2 bowel movements with a consistency of Type 1 or Type 2 according to the BSS per week.
Adequate compliance with the e-diary recording procedure defined as at least 11 of 14 days (≥75%) of the nominal daily data entry.

Exclusion Criteria:

Male gender.
Diagnosis of IBS with a subtype of constipation, mixed IBS, or un-subtyped IBS.
Colonic or major abdominal surgery, any other major abdominal surgery or elective major surgery planned or expected during the study.
History of organic GI abnormalities, inflammatory bowel diseases, complicated diverticulosis, ischaemic colitis, microscopic colitis.
History of pancreatitis, active biliary duct disease, cholecystitis or symptomatic gallbladder stone disease in the previous 6 months.
History of gluten enteropathy or lactose intolerance.
Current or previous diagnosis of neoplasia.
History of endometriosis.
History of positive tests for ova or parasites, or clostridium difficile toxin or occult blood in the stool in the previous 6 months.
History of human immunodeficiency virus infection.
History of major cardiovascular events in the previous 6 months.
Uncontrolled hypertension, insulin-dependent diabetes mellitus or abnormal thyroid function.
Major psychiatric or neurological disorders or unstable medical condition which may compromise the efficacy and safety assessments.
Evidence of clinically significant hepatic disease, severe renal insufficiency or anemia.
Relevant changes in dietary habits, lifestyle, or exercise regimen in the previous 2 months.
Use of prohibited concurrent medication within the previous month such as antibiotics, antimuscarinic drugs, drugs enhancing GI motility and analgesics.
Pregnancy or breastfeeding.
Inability to understand or collaborate throughout the study.
Participation in other clinical studies in the previous 4 weeks or concurrent enrollment in a clinical study.
Any condition that would compromise the well-being of the patient.